MGI Tech and Predica Diagnostics Accelerate Cervical Cancer Screening on DNBSEQ Platforms

MGI Tech Co., Ltd. Netherlands

[e-mail]

About MGI

MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as one of the only providers of a full-stack product portfolio that spans three core segments: SEQ ALL (short- and long-read sequencing), GLI (Generative Lab Intelligence), and Multi-Omics. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

To learn more, please visit MGI Tech, LinkedIn, X, Instagram, and YouTube.

Photo - https://mma.prnewswire.com/media/2935784/E25_Predica_Diagnostics.jpg
Photo - https://mma.prnewswire.com/media/2935785/Figure_1_Optimization_library_preparation_MGI_E25_Total_Assigned_Reads.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/mgi-tech-and-predica-diagnostics-accelerate-cervical-cancer-screening-on-dnbseq-platforms-302715888.html